PDF(Pubmed)
Abstract：
OBJECTIVE: We intended to investigate the risk for second primary malignancy (SPM) development in Laryngeal Cancer (LC) survivors. We conducted a population-based analysis of SPM risk using the National Cancer Institute\'s Surveillance, Epidemiology, and End Results (SEER) database.
METHODS: Data of selected LC survivors from the SEER database between 2000 and 2020 were examined. Standardized Incidence ratios (SIRs) for SPM development were calculated, followed by detailed stratification according to anatomical site and different latency periods.
RESULTS: A total of 8413 SPMs were observed in our extracted cohort. The collective standardized incidence of SPMs was 2.12 (95% CI 2.07-2.17) compared to the US population, with an absolute excess risk (AER) of 201.73 per 10,000 individuals. The highest SPM risks were observed in patients with young age at diagnosis, females, and American Indians/Alaska natives. Increased SPM risks were reported in patients receiving all modalities of treatment including surgery, chemotherapy, and radiotherapy. Most SPMs were detected in solid organs such as the lungs and bronchus, oral cavity and pharynx, and prostate. The highest increased risks of developing SPMs were observed in Trachea, larynx, oral cavity and pharynx, lung and bronchus, and esophagus.
CONCLUSIONS: The risk of SPMs in LC survivors was significantly increased compared to the general US population. Accordingly, a more impactful cancer surveillance strategy for LC patients should be implemented.
METHODS: Data of selected LC survivors from the SEER database between 2000 and 2020 were examined. Standardized Incidence ratios (SIRs) for SPM development were calculated, followed by detailed stratification according to anatomical site and different latency periods.
RESULTS: A total of 8413 SPMs were observed in our extracted cohort. The collective standardized incidence of SPMs was 2.12 (95% CI 2.07-2.17) compared to the US population, with an absolute excess risk (AER) of 201.73 per 10,000 individuals. The highest SPM risks were observed in patients with young age at diagnosis, females, and American Indians/Alaska natives. Increased SPM risks were reported in patients receiving all modalities of treatment including surgery, chemotherapy, and radiotherapy. Most SPMs were detected in solid organs such as the lungs and bronchus, oral cavity and pharynx, and prostate. The highest increased risks of developing SPMs were observed in Trachea, larynx, oral cavity and pharynx, lung and bronchus, and esophagus.
CONCLUSIONS: The risk of SPMs in LC survivors was significantly increased compared to the general US population. Accordingly, a more impactful cancer surveillance strategy for LC patients should be implemented.
摘要：
目的：我们打算调查喉癌（LC）幸存者发生第二原发恶性肿瘤（SPM）的风险。我们使用国家癌症研究所的监测进行了基于人群的SPM风险分析，流行病学,和结束结果(SEER)数据库。
方法：检查了2000年至2020年SEER数据库中选定的LC幸存者数据。计算了SPM发展的标准化发生率（SIR），然后根据解剖部位和不同的潜伏期进行详细的分层。
结果：在我们的提取队列中总共观察到8413个SPM。与美国人群相比，SPM的集体标准化发生率为2.12（95％CI2.07-2.17），绝对超额风险(AER)为201.73/10000个人。在诊断时年龄较小的患者中观察到最高的SPM风险，女性,和美洲印第安人/阿拉斯加土著人。据报道，接受包括手术在内的所有治疗方式的患者的SPM风险增加，化疗,和放射治疗。大多数SPM在肺和支气管等实体器官中检测到，口腔和咽部，还有前列腺.在气管中观察到发展SPM的风险最高。喉部,口腔和咽部，肺和支气管，还有食道.
结论：与普通美国人群相比，LC幸存者中SPM的风险显著增加。因此，应该对LC患者实施更有效的癌症监测策略.
方法：检查了2000年至2020年SEER数据库中选定的LC幸存者数据。计算了SPM发展的标准化发生率（SIR），然后根据解剖部位和不同的潜伏期进行详细的分层。
结果：在我们的提取队列中总共观察到8413个SPM。与美国人群相比，SPM的集体标准化发生率为2.12（95％CI2.07-2.17），绝对超额风险(AER)为201.73/10000个人。在诊断时年龄较小的患者中观察到最高的SPM风险，女性,和美洲印第安人/阿拉斯加土著人。据报道，接受包括手术在内的所有治疗方式的患者的SPM风险增加，化疗,和放射治疗。大多数SPM在肺和支气管等实体器官中检测到，口腔和咽部，还有前列腺.在气管中观察到发展SPM的风险最高。喉部,口腔和咽部，肺和支气管，还有食道.
结论：与普通美国人群相比，LC幸存者中SPM的风险显著增加。因此，应该对LC患者实施更有效的癌症监测策略.
